Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 81.85 EUR -0.55% Market Closed
Market Cap: €1.5B

Net Margin

19%
Current
Improving
by 8.2%
vs 3-y average of 10.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
19%
=
Net Income
€34m
/
Revenue
€179.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
19%
=
Net Income
€34m
/
Revenue
€179.3m

Peer Comparison

Country Company Market Cap Net
Margin
ES
Pharma Mar SA
MAD:PHM
1.4B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Higher than 70% of companies in Spain
Percentile
70th
Based on 821 companies
70th percentile
19%
Low
-9 204.1% — 1.8%
Typical Range
1.8% — 19%
High
19% — 603.4%
Distribution Statistics
Spain
Min -9 204.1%
30th Percentile 1.8%
Median 7.6%
70th Percentile 19%
Max 603.4%

Pharma Mar SA
Glance View

Market Cap
1.5B EUR
Industry
Biotechnology

Nestled in the vibrant biotech landscape of Spain, Pharma Mar SA emerges as a pioneer, weaving the wonders of the sea into groundbreaking medical therapies. Born from the vision of harnessing marine biodiversity, the company delves into the vast oceanic expanse, unearthing bioactive compounds with potential therapeutic uses. This oceanic pursuit forms the backbone of its innovative approach, focusing on oncological drugs derived from the depths of the sea. Their portfolio showcases significant breakthroughs, with products like Yondelis, originally discovered in a sea squirt, reflecting their unique niche in the drug development pipeline. By advancing these marine-based molecules through intensive clinical research, Pharma Mar translates the ocean's secrets into lifesaving treatments, underscoring its hallmark presence in oncology. The company ingeniously monetizes this frontier exploration by orchestrating a business model encompassing rigorous R&D, strategic partnerships, and licensing agreements. Pharma Mar invests heavily in its research, channeling substantial resources into both preclinical and clinical trials to elevate these marine compounds into market-ready drugs. Partnering with global pharmaceutical heavyweights enables them to extend their market reach while sharing development costs and multiplying revenue streams through royalties and milestone payments. Furthermore, licensing their findings expands their financial foothold, allowing them to reap returns on their intellectual exploits without the burden of full-scale commercialization. Pharma Mar’s adept navigation of the pharmaceutical seas has thus firmly anchored its place within the global biotech arena.

PHM Intrinsic Value
82.09 EUR
Fairly Valued
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
19%
=
Net Income
€34m
/
Revenue
€179.3m
What is Pharma Mar SA's current Net Margin?

The current Net Margin for Pharma Mar SA is 19%, which is above its 3-year median of 10.8%.

How has Net Margin changed over time?

Over the last 3 years, Pharma Mar SA’s Net Margin has decreased from 35.2% to 19%. During this period, it reached a low of -1.1% on Jun 30, 2024 and a high of 35.2% on Sep 30, 2022.

Back to Top